|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) patients carrying specific EGFR kinase activating mutations (L858R, delE746-A750) respond well to tyrosine kinase inhibitors (TKIs).
|
27612423 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) sensitive to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) often acquires resistance through secondary EGFR mutations, including the T790M mutation, aberrant c-Met receptor activity, or both.
|
28469968 |
2017 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung carcinomas (NSCLC) with activating L858R or ΔE746-E750 EGFR mutations exhibit elevated EGFR activity and downstream signaling.
|
28801308 |
2017 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung carcinomas (NSCLC) with activating L858R or ΔE746-E750 EGFR mutations exhibit elevated EGFR activity and downstream signaling.
|
28801308 |
2017 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung carcinomas (NSCLC) with activating L858R or ΔE746-E750 EGFR mutations exhibit elevated EGFR activity and downstream signaling.
|
28801308 |
2017 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and erlotinib.
|
29514601 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and erlotinib.
|
29514601 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and erlotinib.
|
29514601 |
2018 |
|
rs397517096
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.
|
29673089 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) patients with EGFR mutations initially respond well to EGFR tyrosine kinase inhibitors (TKIs) but eventually exhibit acquired or innate resistance to the therapies typically due to gene mutations, such as EGFR T790M mutation or a second mutation in the downstream pathways of EGFR.
|
29789542 |
2018 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or L858R mutation usually respond to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), whereas T790M mutation and exon 20 insertion are frequently resistant to EGFR-TKIs.
|
31425965 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or L858R mutation usually respond to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), whereas T790M mutation and exon 20 insertion are frequently resistant to EGFR-TKIs.
|
31425965 |
2019 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or L858R mutation usually respond to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), whereas T790M mutation and exon 20 insertion are frequently resistant to EGFR-TKIs.
|
31425965 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or L858R mutation usually respond to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), whereas T790M mutation and exon 20 insertion are frequently resistant to EGFR-TKIs.
|
31425965 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
T790M may not be a rare event before or after TKI therapy in patients with NSCLC with EGFR-activating mutations.
|
22215752 |
2012 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
|
24685306 |
2014 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
T790M germline mutations occurred in approximately 1% of non-small-cell lung cancer cases and in less than one in 7500 subjects without lung cancer.
|
24736066 |
2014 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
T790M alleles were then analyzed using ddPCR in 59 plasma samples from 24 NSCLC patients with EGFR mutations, and compared to the T790M status which were determined thorough re-biopsies.
|
28405680 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
T790M-negative patients with EGFR mutation-positive NSCLC are more likely to benefit from nivolumab after EGFR-TKI treatment, possibly as a result of a higher PD-L1 expression level, than are T790M-positive patients.
|
28407039 |
2017 |
|
rs1057519861
|
|
|
0.100 |
GeneticVariation |
BEFREE |
C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?
|
30128066 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring <i>EGFR</i> Mutations.
|
30150444 |
2018 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
L858R point mutation is the most common oncogenic mutation in EGFR tyrosine kinase domain in patients with EGFR-mutated NSCLC.
|
31116768 |
2019 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
L858R point mutation is the most common oncogenic mutation in EGFR tyrosine kinase domain in patients with EGFR-mutated NSCLC.
|
31116768 |
2019 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
L858R point mutation is the most common oncogenic mutation in EGFR tyrosine kinase domain in patients with EGFR-mutated NSCLC.
|
31116768 |
2019 |
|
rs1057519861
|
|
|
0.100 |
GeneticVariation |
BEFREE |
C797S does not occur in TKI-naïve NSCLCs and provide evidence that screening for this mutation before TKIs administration may not be necessary.
|
31243697 |
2019 |